Harvard Bioscience (HBIO) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to -$1.2 million.
- Harvard Bioscience's Income from Continuing Operations rose 7430.24% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.8 million, marking a year-over-year decrease of 27876.57%. This contributed to the annual value of -$12.4 million for FY2024, which is 26325.04% down from last year.
- Per Harvard Bioscience's latest filing, its Income from Continuing Operations stood at -$1.2 million for Q3 2025, which was up 7430.24% from -$2.3 million recorded in Q2 2025.
- Harvard Bioscience's 5-year Income from Continuing Operations high stood at $2.4 million for Q2 2022, and its period low was -$50.3 million during Q1 2025.
- For the 5-year period, Harvard Bioscience's Income from Continuing Operations averaged around -$4.2 million, with its median value being -$1.3 million (2023).
- Examining YoY changes over the last 5 years, Harvard Bioscience's Income from Continuing Operations showed a top increase of 69048.78% in 2022 and a maximum decrease of 189411.76% in 2022.
- Quarter analysis of 5 years shows Harvard Bioscience's Income from Continuing Operations stood at $590000.0 in 2021, then tumbled by 466.78% to -$2.2 million in 2022, then rose by 15.99% to -$1.8 million in 2023, then surged by 102.75% to $50000.0 in 2024, then tumbled by 2568.0% to -$1.2 million in 2025.
- Its Income from Continuing Operations stands at -$1.2 million for Q3 2025, versus -$2.3 million for Q2 2025 and -$50.3 million for Q1 2025.